Sharon Robertson is a nationally recognized leader in complex, multi-district class actions, with a particular focus on pharmaceutical antitrust litigation.
Sharon spearheads Cohen Milstein’s efforts in pay-for-delay pharmaceutical antitrust lawsuits, a cutting-edge and industry-defining area of law, which allege that the defendant brand manufacturer entered into non-competition agreements with generic manufacturers to delay entry of lower-priced generic products. She also leads the firm’s generic price-fixing cases, which allege that certain generic drug manufacturers conspired to inflate the prices of generic drug products.
These cases come on the heels of a government investigation led by the U.S. Department of Justice alleging similar conduct, which, while ongoing, has already resulted in indictments and guilty pleas.
Sharon is also an accomplished trial lawyer, having served as a trial team member in two of the largest antitrust cases tried to verdict:
- In re Urethanes Antitrust Litigation, where the jury returned a $400 million verdict, which was trebled by the Court, as required by antitrust law, resulting in the largest price-fixing verdict in U.S. history.
- In re Nexium Antitrust Litigation, the first pharmaceutical antitrust case to go to trial following the Supreme Court’s landmark decision in FTC v. Actavis, 570 U.S. 756 (2013).
Sharon is a leader inside the firm as well. She serves on the Executive Committee. Prior to joining the Executive Committee, Sharon served as a Co-Chair of the Professional Development and Mentoring Committee and as a member of the Hiring & Diversity Committee for over a decade.
While attending law school, Sharon was an intern in the Litigation Bureau of the Office of the New York State Attorney General and the United States Court of Appeals for the Second Circuit. Additionally, while in law school, she was selected as an Alexander Fellow and spent a semester serving as a full-time Judicial Intern to the Hon. Shira A. Scheindlin, U.S. District Court for the Southern District of New York.
In law school, Sharon served as notes editor for the Cardozo Public Law, Policy and Ethics Journal.
Prior to attending law school, Sharon worked on the campaign committee of Councilman John Liu, the first Asian American to be elected to New York City’s City Council.
- New York State Bar Association
- Executive Committee, Antitrust Section, New York State Bar Association
- New Jersey
- New York
- Benjamin N. Cardozo School of Law, J.D., 2006
- University at Binghamton - State University of New York, B.A., magna cum laude, 2003
- Alexander Fellow, the Hon. Shira A. Scheindlin, U.S. District Court for the Southern District of New York
- Intern, United States Court of Appeals for the Second Circuit
- Intern, Litigation Bureau, Office of the New York State Attorney General
Current Cases
In re Intuniv Antitrust Litigation
In re: Intuniv Antitrust Litigation (D. Mass.): On July 2, 2024, the Court granted preliminary approval of a $58 million settlement between a certified class of direct purchasers and Shire after seven-and-a-half years of hard-fought litigation. The settlement follows a $19.9 million settlement between a certified class of direct purchasers and Actavis, which was granted final approval by the court on December 9, 2020. Pending final approval, total settlements for the direct purchaser class will come to $80 million. Plaintiffs allege that the Actavis, along with fellow pharmaceutical manufacturer Shire, conspired to delay competition for generic versions of Intuniv, an attention deficit hyperactivity disorder (ADHD) medication, causing the direct purchasers to pay an inflated price for Intuniv. Cohen Milstein plays a significant role in representing the Direct Purchaser Class.
In re Seroquel XR Antitrust Litigation
In re Seroquel XR Antitrust Litigation (D. Del.): Plaintiffs allege that Defendant AstraZeneca Pharmaceuticals LP struck deals with generic drug manufacturers Handa Pharmaceuticals LLC, Par Pharmaceutical Inc. and Accord Pharmaceuticals Inc., inducing the generics to delay launching generic versions of Seroquel XR, AstraZeneca's prescription drug treatment for schizophrenia, bipolar disorder and depression, for five years in exchange for AstraZeneca committing to delay the launch of its own authorized generic.
In re Tracleer Antitrust Litigation
Baltimore v. Actelion Pharmaceuticals LTD (D. Md.): Cohen Milstein is court-appointed Co-Lead Class Counsel, representing the End-Payor Class in this certified class action against Actelion Pharmaceuticals LTD, manufacturer of the brand prescription drug bosentan, marketed as Tracleer. Plaintiffs allege that Defendant Actelion engaged in an anticompetitive scheme to withhold samples of its life-saving pulmonary arterial hypertension medication from would-be rivals, under the guise of the REMs program, which conduct ultimately delayed generic competition.
In Re Axon VieVu Antitrust Litigation
In Re Axon VieVu Antitrust Litigation (D.N.J.): Cohen Milstein, as Co-Lead Counsel, represents the Mayor and City Council of Baltimore and other municipalities in this consolidated antitrust class action, alleging that Axon unlawfully monopolized the markets for body-worn camera systems and long-range conducted energy weapons, such as Tasers, through acquiring its largest competitor and signing decade-long non-compete, market allocation, and no-poach agreements with its main competitor.
Rotavirus Antitrust Litigation
Baltimore v. Merck (E.D. Pa.): Cohen Milstein is representing the City of Baltimore in this putative antitrust class action, alleging that Merck’s bundled “loyalty” program for the rotavirus vaccine called RotaTeq is a scheme to leverage and maintain its monopoly in Rotavirus vaccines. As a consequence, Plaintiffs claim that Merck is able to charge customers supercompetitive prices.
In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation
In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation (E.D.N.Y.): Cohen Milstein represents gasoline retailers in numerous states in an antitrust class against Visa, Inc. and MasterCard, Inc. for orchestrating an anticompetitive scheme artificially inflating the “interchange fees” charged to process credit card transactions on their networks.
In re Actos Antitrust Litigation
In re Actos Antitrust Litigation (S.D.N.Y.): Cohen Milstein represents End-Payor Plaintiffs in this antitrust action, alleging that Defendant Takeda engaged in anticompetitive conduct related to the listing of certain patents in the FDA’s Orange Book thereby resulting in unlawful delays to the market entry of generic versions of Takeda’s diabetes drug, Actos.
Past Cases
In re Ranbaxy Generic Drug Application Antitrust Litigation
In re Ranbaxy Generic Drug Application Antitrust Litigation (D. Mass.): We represent the Direct Purchaser Class in this antitrust, federal RICO, and state consumer protection MDL, alleging Ranbaxy manipulated the U.S. Food and Drug Administration’s generic drug approval process to block competitors from coming to market and forcing purchasers to pay supracompetitive prices for its valganciclovir hydrochloride and valsartan products. On the eve of trial, Ranbaxy settled with the Direct Purchaser Class for $340 million.
In re Lidoderm Antitrust Litigation
In re Lidoderm Antitrust Litigation (N.D. Cal.): Cohen Milstein served as Co-Lead Counsel for the End-Payor Class in a suit alleging that Endo and Teikoku, manufacturers of the Lidoderm patch, paid Watson Pharmaceuticals to delay its generic launch. The case settled on the eve of trial and on September 20, 2018, Plaintiffs obtained final approval of a $104.75 million settlement – more than 40% of Plaintiffs’ best-case damages estimate.
In re Loestrin 24 FE Antitrust Litigation
In re Loestrin 24 FE Antitrust Litigation (D.R.I.): We served as Co-Lead Counsel for the End-Payor Plaintiffs in a case alleging that Warner Chilcott PLC entered into agreements to delay the introduction of a generic version of the contraceptive drug Loestrin and thereafter engaged in a “product hop” to further impede generic entry. The case settled on the last business day before trial for $63.5 million – representing one of the largest settlements in a federal generic suppression case in over a decade. On September 1, 2020, the settlements received final approval.
In re Lipitor Antitrust Litigation
In re Lipitor Antitrust Litigation (D.N.J.): Plaintiffs allege that Pfizer, the manufacturer of the cholesterol drug Lipitor, the best-selling drug in pharmaceutical history, conspired with Ranbaxy, the generic manufacturer, to delay its introduction of a generic Lipitor product. On October 1, 2024, the Court granted final approval of a $35 million settlement against Pfizer for its role in the alleged anticompetitive scheme. Cohen Milstein was Co-Lead Counsel to the End-Payor Plaintiffs class.
In re Solodyn Antitrust Litigation
In re Solodyn Antitrust Litigation (D. Mass.): We served as a member of the executive committee and Ms. Robertson played a significant role in coordinating discovery on behalf of the End-Payor Plaintiffs. The case, which settled mid-trial, resulted in a $43 million recovery for the Class.
In re Blood Reagents Antitrust Litigation
In re Blood Reagents Antitrust Litigation (E.D. Pa.): Plaintiffs alleged that the two leading producers of blood reagents, Ortho–Clinical Diagnostics, Inc. and Immucor, Inc., conspired to raise prices on traditional blood reagents. In September 2012, Immucor reached a settlement with Plaintiffs. On July 19, 2017, the Court denied in part Ortho’s Motion for Summary Judgement. Ms. Robertson was slated to serve as one of four lead trial counsel in the case, which was set for trial in June of 2018 but ultimately settled for a total recovery of $41.5 million.
In re Urethane Antitrust Litigation
In re Urethane Antitrust Litigation (D. Kan.): Cohen Milstein served as Co-Lead Counsel on behalf of a class of direct purchasers of urethane chemicals who were overcharged as a result of a nationwide price-fixing conspiracy. Cohen Milstein and their co-counsel prevailed at trial and obtained a judgment of $1.06 billion against Dow Chemical in 2013. Dow ultimately settled for $835 million while the case was on appeal before the Supreme Court, bringing the total recovery, including prior settlements with other defendants, to $974 million – nearly 250% of the damages found by the jury. The Honorable John W. Lungstrum, who presided over the trial, remarked: “In almost 25 years of service on the bench, this Court has not experienced a more remarkable result.”
ExxonMobil -Villagers of Aceh Litigation
John Doe I v. ExxonMobil Corporation (D.D.C.): Cohen Milstein represented eleven villagers from Aceh, Indonesia, who alleged that they or their relatives endured horrific human rights abuses, including murder, torture, sexual violence, and kidnapping, at the hands of Indonesian soldiers contracted by ExxonMobil to guard its oil operations in the region. On May 15, 2023, a week before a jury trial was to start and after 22 years of litigation, the case settled. Although the case was litigated in U.S. federal court, Indonesian law applied to Plaintiffs’ claims and was applied by the court. The case set numerous legal precedents during its 20-year history, during which it saw two trips to the D.C. Circuit Court of Appeals (decided January 2007 and July 2011) and one to the Supreme Court (certiorari was denied in 2008). Each time, novel issues of foreign policy impact, extraterritorial jurisdiction, and choice of law were briefed and considered by the Court of Appeals. In August 2022, months before trial, the district court largely denied ExxonMobil’s motion for summary judgment, finding most of its arguments “entirely meritless.” Cohen Milstein and co-counsel were awarded the 2024 Public Justice Trial Lawyer of the Year Award for the successful resolution of this case.
Investigations
PVC Pipe Price-Fixing Investigation
Attorney Advertising We are investigating potential antitrust violations in the PVC Pipe industry. If you purchased PVC municipal water pipes or electrical conduit pipes in the past four years, consider contacting us to participate in our investigation. Illegal price-fixing may have forced contractors, builders, and other purchasers to overpay for certain PVC pipe products in […]
- Lawdragon 500 Leading Litigators in America (2025)
- Lawdragon 500 Global Plaintiff Lawyers (2024)
- Chambers USA, Top Ranked Lawyer Antitrust: Plaintiff – New York & Nationwide (2020-2024)
- Legal 500, Leading Lawyers (2022-2024)
- Lawdragon 500 Leading Lawyers in America (2019-2024)
- Lawdragon 500 Leading Plaintiff Financial Lawyers (2019-2024)
- Benchmark Litigation, Future Stars (2023)
- The National Law Journal, Elite Women of the Plaintiffs Bar (2019)
- Law360, Life Sciences MVP (2019)
- American Antitrust Institute, Outstanding Antitrust Litigation Achievement by a Young Lawyer (2018)
- Legal 500, Next Generation Partner (2017-2021)
- The New York Law Journal, Rising Star (2018)
- Benchmark Litigation, 40 Under 40 Hot List (2018-2022)
- Law360, Rising Star (2018)
- Super Lawyers (2019-2023)
- Super Lawyers, Rising Star (2014-2016)
September 6, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified
A Maryland federal judge refused Friday to toss an antitrust suit accusing Actelion Pharmaceuticals of illegally denying generics companies the samples they needed to produce generic versions of its hypertension drug Tracleer, while separately certifying a class composed of “hundreds” of insurers and self-funded employers. U.S. District Judge George L. Russell III issued two omnibus […]
In the News | Law360
September 9, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified
A Maryland federal judge refused Friday to toss an antitrust suit accusing Actelion Pharmaceuticals of illegally denying generics companies the samples they needed to produce generic versions of its hypertension drug Tracleer, while separately certifying a class composed of “hundreds” of insurers and self-funded employers. U.S. District Judge George L. Russell III issued two omnibus […]
In the News | Law360
August 28, 2024
Merck Must Face Class Claims In Vaccine Antitrust Suit
Merck cannot strike class claims in antitrust litigation over its rotavirus vaccine, a Pennsylvania federal judge ruled Wednesday, while also allowing the city of Baltimore to eliminate redundancies in its complaint. U.S. District Judge Gerald A. McHugh disagreed with Merck’s position that there was no way to feasibly identify class members and that continued class […]
In the News | Law360
August 28, 2024
Lipitor Buyers Seek Final OK For $35M Deal In Antitrust Fight
End-payor plaintiffs asked a New Jersey federal judge Tuesday to give final approval of a $35 million settlement resolving their antitrust claims against Pfizer over the cholesterol medication Lipitor. The proposed settlement will put an end to claims from the end payors, which represent a class of third-party payors and a class of consumers who […]
In the News | Law360
August 9, 2024
Takeda Should Face Certified Antitrust Classes, Judge Says
A New York federal judge on Friday recommended certifying two classes of direct purchasers and end payors in consolidated antitrust actions accusing Takeda Pharmaceuticals Co. of unlawfully inflating the price of its diabetes treatment Actos by delaying entry of generic alternatives. U.S. Magistrate Judge Stewart D. Aaron’s report and recommendation said both groups’ motions for […]
In the News | Law360
July 30, 2024
Public Justice Announces Winner of 2024 Trial Lawyer of the Year Award
Each year, Public Justice is proud to present its Trial Lawyer of the Year Award to the trial attorney or legal team who made the greatest contribution to the public interest within the past year by trying or settling a socially significant case. This year’s winner is the legal team for John Doe I v. […]
In the News | Public Justice
May 14, 2024
Shire Settles Claims Over Alleged ADHD Generic Delay
Purchasers of the medication Intuniv have settled a years-old class action against drugmaker Shire PLC and manufacturer Actavis over allegations that the companies struck an anti-competitive deal to delay the production of a generic version of the attention-deficit/hyperactivity disorder drug. . . . The class is represented by Lauren G. Barns, Thomas Sobol, Abbye Ognibene, […]
In the News | Law360
April 10, 2024
Sharon Robertson to Speak at ABA Antitrust Spring Meeting
Sharon Robertson will speak on the panel “Effective Litigation Strategies in Monopolization Cases” as part of the American Bar Association’s 72nd Antitrust Spring Meeting, to be held April 10-12 in Washington, DC. Participants will explore topics including: The Spring Meeting is the world’s largest gathering of competition, consumer protection, and data privacy professionals. It draws […]
Events | American Bar Association Antitrust Law Section
November 21, 2023
Baltimore Merck Vax Suit Proceeds But Utah, Idaho Claims Cut
The bulk of Baltimore’s proposed class action against Merck over its rotavirus vaccine bundling can go to class certification, a Pennsylvania federal judge has ruled, finding that Merck may very well have violated antitrust laws through its “loyalty” program for an essential pediatric vaccine, but also tossing two claims under Idaho and Utah antitrust law. […]
In the News | Law360
December 8, 2023
Sharon K. Robertson Co-Chairs PLI’s 2023 Class Action Litigation Conference
Sharon K. Robertson, a partner in our Antitrust practice, will co-chair Practising Law Institute’s (PLI) 2023 Class Action Litigation Conference. Who Should Attend This program will benefit outside attorneys who are prosecuting or defending class action cases as well as in-house counsel who want to gain a competitive edge in this fast-moving field. Why You Should Attend […]
Events | Practising Law Institute
October 10, 2023
Lipitor Hearing Punted As Ranbaxy Counsel ‘Trapped’ In Israel
A New Jersey federal judge on Tuesday agreed to postpone class certification hearings in antitrust multidistrict litigation over cholesterol medication Lipitor after Ranbaxy Laboratories Ltd. told the court an unidentified attorney is “currently trapped in the war zone in Israel with no foreseeable way to get out.” A closeup of a white drug bottle with […]
In the News | Law360
May 25, 2023
Sharon Robertson Addresses Biden Administration’s Antitrust Policy at Milton Handler Lecture
Sharon Robertson has been invited to speak at the 50th Anniversary Milton Handler Lecture on Antitrust at the New York City Bar Association on Thursday, May 25, 2023 at 6:30 p.m. Program Description: This year’s Handler Lecture will be given by Timothy Wu, Julius Silver Professor of Law, Science and Technology at Columbia Law School, and […]
Events
April 18, 2023
Merck, Glenmark Settle With Direct Purchasers In Zetia Case
Drug companies Merck and Glenmark Pharmaceuticals have settled a group of direct purchasers’ claims that they gouged drug buyers via an anti-competitive 2010 pay-for-delay patent settlement, leaving one fewer group of plaintiffs just as jury selection in a highly anticipated trial is set to kick off, according to court records. The multidistrict litigation trial in […]
In the News | Law360
April 13, 2023
Covington Partner Must Testify Live In Zetia Trial, Judge Told
Drug buyers seeking billions in damages in an antitrust pay-for-delay trial against pharma companies Merck and Glenmark urged a D.C. federal judge Wednesday to force Covington & Burling partner Timothy Hester to livestream testimony, citing the finding of the trial’s presiding judge that Hester is a “key” witness. The case concerns claims that the 2010 […]
In the News | Law360
March 7, 2023
Merck Hit With 3rd-Party Payor Suit Over Vaccine Bundling
Merck Sharp & Dohme Corp. has been hit with another proposed class action over its allegedly anti-competitive practice of bundling several of its vaccines for children to maintain its monopoly power in the rotavirus vaccine market, this time brought by third-party payors who indirectly paid for or reimbursed rotavirus vaccines. In the suit filed Friday, […]
In the News | Law360
November 9, 2022
Sharon Robertson to Moderate Panel, When Public and Private Enforcers Collaborate
Sharon K. Robertson will moderate a panel at the American Antitrust Institute’s (AAI) annual Private Antitrust Enforcement Conference on November 9. The panel, “Beneficial Coordination: When Public and Private Enforcers Collaborate,” will explore key issues, challenges, and best practices in the coordination of public and private antitrust enforcement. Now in its 16th year, the Private […]
Articles | AAI Private Antitrust Enforcement Conference
September 7, 2022
Merck, Glenmark Antitrust MDL Must Go to Jury, Judge Says
A Virginia magistrate judge has recommended denying Merck and Glenmark’s bids to end antitrust multidistrict litigation accusing the drugmakers of conspiring to delay generic competition for the branded cholesterol medication Zetia, finding there are numerous material factual disputes that should go to a jury. In a 74-page report filed Friday, U.S. Magistrate Judge Douglas E. […]
In the News | Law360
April 29, 2022
Ranbaxy Buyers’ $485M Deal in Generics MDL Gets Initial Nod
Ranbaxy Pharmaceuticals drug purchasers nabbed initial approval of a $485 million global settlement struck in March over claims the drugmaker manipulated the U.S. Food and Drug Administration’s generic-drug approval process to box out competitors. U.S. District Court Judge Nathanial M. Gorton preliminary approved the two deals on Thursday in Massachusetts federal court and signed off […]
In the News | Law360
February 11, 2022
Credit Suisse Investors Ink $25M ‘Icebreaker’ Rate Swaps Deal
Institutional investors leading sprawling multidistrict litigation against nearly a dozen megabanks that allegedly colluded to control the interest rate swaps market told a New York federal judge Friday they’ve reached a $25 million “icebreaker” settlement with Credit Suisse. Along with the $25 million cash award, the proposed settlement calls for Credit Suisse Group AG to […]
In the News | Law360
January 31, 2022
DOJ Tells DC Circ. to Reassemble States’ Facebook Claims
The U.S. Department of Justice has thrown its weight behind 48 attorneys general trying to revive their lawsuit accusing Facebook of illegally monopolizing personal social networking services, telling the D.C. Circuit that a district judge wrongly broke the suit down without looking at the allegations cumulatively. The DOJ Antitrust Division was one of several parties […]
In the News | Law360
November 23, 2021
Ranbaxy Can’t Shake MDL Antitrust Claims as Trial Nears
Ranbaxy Pharmaceuticals Inc. didn’t need to ever sell a dose of a drug to have wielded monopoly power over it, a Boston federal judge ruled Monday, rejecting the company’s bid for an early win on antitrust claims in the multidistrict suit. . . . The antitrust suit, set for a Jan. 10 trial, alleges that […]
In the News | Law360
May 14, 2021
Buyers Win Cert. in Ranbaxy Generic-Drug Antitrust Case
A Massachusetts federal court on Friday certified classes for two groups of buyers accusing Ranbaxy Pharmaceuticals of delaying generic versions of three different drugs by manipulating the regulatory approval system. U.S. District Judge Nathaniel M. Gorton issued an order granting class certification requests from direct purchasers, including drug wholesalers, and from end-payors, such as health […]
In the News | Law360
April 13, 2021
4th Circ. Revives Antitrust Suit Over Actelion’s Drug Tracleer
The Fourth Circuit on Tuesday revived Baltimore’s antitrust suit accusing Actelion Pharmaceuticals of illegally pumping up the price of its drug Tracleer after the patent expired, reversing a decision that the case was time-barred and finding that it was filed within the statute of limitations. A three-judge panel vacated a lower court’s dismissal order and […]
In the News | Law360
March 8, 2021
Sharon K. Robertson Invited to Speak on Cardozo Law Alumni Association Women’s History Month Panel
Sharon K. Robertson, a partner in our Antitrust practice, will speak on the Cardozo Law Alumni Association’s virtual panel “What It’s Like to Be a Litigator and Defying Gender Norms” on March 8, 2021. The panel is part of the Alumni Association’s “Women Lead the Law” event series, celebrating Women’s History Month. The discussion, featuring women […]
Events
January 25, 2021
Sharon K. Robertson Invited to Speak on Developments in Cartel Enforcement and Practice
Sharon K. Robertson, a partner in Cohen Milstein’s Antitrust practice, has been invited to speak at the New York State Bar Association (NYSBA) Antitrust Law Section Annual Meeting on January 25, 2021. Ms. Robertson will speak on the panel “Developments in Cartel Enforcement and Practice,” discussing: The state of U.S. and EU cartel enforcement; Leniency developments; Cross-border coordination among […]
Events | NYSBA Antitrust Law Section Annual Meeting
November 13, 2020
3 Firms Score End-Payor Co-Lead Role in Seroquel XR Cases
A Delaware federal judge on Friday tapped three firms — Grant & Eisenhofer PA, Cohen Milstein Sellers & Toll PLLC and Shepherd Finkelman Miller & Shah LLP — to lead the proposed end-payor class accusing AstraZeneca of paying off generic-drug makers to protect its brand antipsychotic drug Seroquel XR. U.S. District Judge Colm F. Connolly […]
In the News | Law360
November 9, 2020
Sharon Robertson to Speak at the Duke-Bolch Judicial Institute’s Mass-Tort MDL Certificate Program
Sharon K. Robertson, a partner in Cohen Milstein’s Antitrust practice, has been invited to speak at the Duke Law School Bolch Judicial Institute’s Mass-Tort MDL Certificate Program, being held via webcast on November 9, 2020. The 2020 program will feature courses taught by experienced MDL judges, preeminent lead counsel, and MDL committee chairs, and it will offer […]
Events
September 2, 2020
$184M Settlements OK’d in Loestrin Buyers’ Antitrust Row
A Rhode Island federal judge has given the final green light to deals totaling about $183.5 million to settle allegations that Lupin and a pair of Allergan units worked to sideline generic alternatives of the birth control drug Loestrin. On Tuesday, U.S. District Judge William E. Smith granted final approval to a trio of settlements […]
In the News | Law360
August 24, 2020
Zetia Buyers Granted Cert. Despite Small Class Size
A Virginia federal judge granted class certification Friday to Zetia direct buyers accusing Merck and Glenmark Pharmaceuticals of conspiring to keep a generic version of the cholesterol drug off the market, rejecting attacks on the small size of the class and the companies representing them. U.S. District Judge Rebecca Beach Smith fully adopted the recommendation […]
In the News | Law360
August 19, 2020
Actavis Inks Settlement in ADHD Drug Antitrust Suit
Pharmaceutical company Actavis told a Massachusetts federal court Wednesday that it had reached a settlement with the direct purchaser class in a lawsuit that accused the company, along with fellow pharma company Shire, of conspiring to delay sales of a generic version of the attention deficit hyperactivity disorder medication Intuniv. In a letter, Christopher T. […]
In the News | Law360
March 9, 2020
Judge OKs Par’s Settlement in Zetia Pay-For-Delay Case
A Virginia federal judge has given the final greenlight to a settlement that knocks Par Pharmaceutical out of a massive suit accusing Merck and Glenmark of plotting to hold off generic versions of Zetia and inflating the cholesterol drug’s costs. Par, which got roped into the case as a distributor to wholesale and retail drug […]
In the News | Law360
January 7, 2020
Allergan Settles Pay-for-Delay Lawsuit for $300M
Allergan agreed to pay $300 million to settle a lawsuit claiming two of its subsidiaries, Warner Chilcott and Watson Pharmaceuticals, partnered in a pay-for-delay deal that violated antitrust laws, the drugmaker said Jan. 6. The lawsuit, filed in 2013, claimed Warner Chilcott entered into agreements with Watson and generic drugmaker Lupin Pharmaceuticals to delay a generic version […]
In the News | Becker’s Hospital Review
November 27, 2017
Pfizer Wants Justices to Review Lipitor Antitrust Ruling
Pfizer Inc. and generic-drug maker Ranbaxy Inc. have asked the U.S. Supreme Court to review a decision by the Third Circuit to revive allegations in multidistrict litigation accusing Pfizer of making an illegal reverse payment to keep Ranbaxy’s generic version of cholesterol drug Lipitor off the market, saying antitrust scrutiny isn’t appropriate for “commonplace” and […]
In the News | Law360
February 26, 2016
Dow Will Pay $835 Million in Polyurethane Price Fixing Case
Dow Chemical agreed to pay $835 million to settle a decade-long lawsuit on price fixing, saying it had less chance of winning its petition at the Supreme Court after the death of Justice Antonin Scalia. The chemicals company was found liable by a federal jury in Kansas in February 2013 in the class-action lawsuit, which […]
In the News | Reuters
June 27, 2013
Big Suits: In Re Urethane Antitrust Litigation
On May 15 a federal district court judge trebled a $400 million verdict in a class action in which customers had alleged that The Dow Chemical Company fixed prices for the chemical urethane. The $1.2 billion award, by U.S. District Judge John Lungstrum in Kansas City, Kansas, was by far the largest this year as […]
In the News | The American Lawyer
June 3, 2011
Huntsman To Pay $33M To Exit Urethane Antitrust MDL
Huntsman International LLC has agreed to pay $33 million to settle claims from direct purchasers in multidistrict urethane antitrust litigation, while bankrupt Lyondell Chemical Co. likewise reached a deal to exit the long-running case in Kansas, the plaintiffs said Thursday. Seegott Holdings Inc., Quabaug Corp. and Industrial Polymers Inc. — the representatives for the direct […]
In the News | Law360